The burden of mucosal barrier injury laboratory-confirmed bloodstream infection among hematology, oncology, and stem cell transplant patients

Infection Control and Hospital Epidemiology

Volumn 36, Issue 2, 2015, Pages 119-124

  Metzger, Kristen E ^a   Rucker, Yvonne ^a   Callaghan, Mary ^a   Churchill, Michelle ^a,c   Jovanovic, Borko D ^b   Zembower, Teresa R ^a,b   Bolon, Maureen K ^a,b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; CLINICAL FEATURE; COMPARATIVE STUDY; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI INFECTION; FEMALE; HEMATOLOGY; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ONCOLOGY; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STEM CELL TRANSPLANTATION; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME; ADVERSE EFFECTS; BACTEREMIA; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETER; CLASSIFICATION; CROSS INFECTION; FUNGEMIA; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFECTION CONTROL; INJURIES; MICROBIOLOGY; MIDDLE AGED; MUCOSA; NEOPLASMS; YOUNG ADULT;

ADULT; AGED; BACTEREMIA; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETERS; CROSS INFECTION; FEMALE; FUNGEMIA; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION CONTROL; MALE; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84922749253     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1017/ice.2014.38     Document Type: Article

References (19)

1. Digiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999;160:976-981.
2. Warren DK, Quadir WW, Hollenbeak CS, Elward AM, Cox MJ, Fraser VJ. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med 2006;34:2084-2089.
3. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000;132:391-402.
4. Elward AM, Hollenbeak CS, Warren DK, Fraser VJ. Attributable cost of nosocomial primary bloodstream infection in pediatric intensive care unit patients. Pediatrics 2005;115:868-872.
5. Centers for Disease Control and Prevention. Operational guidance for acute care hospitals to report central line-associated blood stream infection (CLABSI) data to CDC’s NHSN for the purpose of fulfilling CMS’s Hospital Inpatient Quality Reporting (IQR) requirements. Available at: http://www.cdc.gov/nhsn/PDFs/FINAL-ACH-CLABSI-Guidance.pdf. Accessed October 11, 2013.
6. Steinberg JP, Robichaux C, Chernetsky Tejedor S, Dent Reyes M, Jacob JT. Distribution of pathogens in central line-associated bloodstream infection among patients with and without neu- tropenia following chemotherapy: evidence for a proposed modification to the current surveillance definition. Infect Control Hosp Epidemiol 2013;34:171-175.
7. Steinberg JP, Coffin SE. Improving the central line-associated bloodstream infection surveillance definition: a work in progress. Infect Control Hosp Epidemiol 2013;34:777-779.
8. Pehar M, Ristaino P, Budd AP, et al. Application of the National Healthcare Safety Network (NHSN) central line-associated bloodstream infection (CLA-BSI) definition to oncology patients: impact in the trenches. Presented at Fifth Decennial Conference on Healthcare-Associated Infections; Atlanta, Georgia; March 18-22, 2010 (Abstract 660).
9. Sexton DJ, Chen LF, Anderson DJ. Current definitions of central-line associated bloodstream infections: is the emperor wearingclothes? Infect Control Hosp Epidemiol 2010;31:1286-1289.
10. Fraser TG, Gordon SM. CLABSI rates in immunocompromised patients: a valuable patient centered outcome? Clin Infect Dis 2011;52:1446-1450.
11. O’Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2011;39:S1-S34.
12. Marschall J, Mermel LA, Fakih M, et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014;35:753-771.
13. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter‐related BSIs in the ICU. N Engl J Med 2006;355:2725-2732.
14. Dudek MA, Weiner LM, Allen-Bridson K, et al. National Healthcare Safety Network (NHSN) report, data summary for 2012, device-associated module. Am J Infect Control2013;41:1148–1166.
15. Tancrede CH, Andremont AO. Bacterial translocation and gram- negative bacteremia in patients with hematological malignancies. J Infect Dis 1985;152:99-103.
16. See I, Iwamoto M, Allen-Bridson K, Horan T, Magill SS, Thompson ND. Mucosal barrier injury laboratory-confirmed bloodstream infection: results from a field test of a new National Healthcare Safety Network definition. Infect Control Hosp Epidemiol 2013;34:769-776.
17. Centers for Disease Control and Prevention. Central line-associated bloodstream infection (CLABSI) event. Available at: http:// www.cdc.gov/nhsn/PDFs/pscManual/4PSC_CLABScurrent.pdf. Accessed October 2, 2013.
18. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014;120:1453-1461.
19. Gibson RJ, Keefe DM, Lalla RV, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2013;21:313-326.